Intellia Therapeutics (NTLA) 5 May 222022 Q1 Earnings call transcript

Good morning. My name is Drew, and I will be your conference operator today, and welcome to the Intellia Therapeutics First Quarter 2022 earnings conference call. [Operator Instructions]. At this time, I would like to turn it over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. Please proceed.

operator. you, Thank everyone. Good morning, Intellia Therapeutics Earnings to quarter first Call. Welcome XXXX on Intellia Earlier well release discussion issued outlining morning, as call. the for as press quarter a this this company's topics today's progress Intellia's be found Investors section This release website on intelliatx.com. can at and the Media of on is live, archived call website. replay will and This company's a being be broadcast the you management potential this refer a and that during listeners time, to minute remind statements filings SEC I At our uncertainties. discussion forward-looking call, to would may Intellia available a ask for certain like that risks to take sec.gov make this at and of All undertakes is no information current unless call update Intellia to and information this today, presented duty law. this required as on by of

John offer we as up Lebwohl, program. Q&A. the recap progress, concluding with Scientific Laura R&D I'll company's Officer. review will Dr. Glenn the highlights. well will Leonard, progress Chief from of Joining NTLA-XXXX recap before overview call over from Chief Glenn with clinical me will Executive first-in-human the John an then financial quarter. CEO, call remarks and the Chief John? results turn across study first open Intellia's for our recent Sepp-Lorenzino, recent Chief the Officer; then of Dr. David Dr. as some Officer; Laura and will our begin that Financial Goddard, business the Intellia for John are our will Medical Officer; David update side to

future the the toolbox, you to and of spectrum for and editing on progress At pipeline, core we're harness our editing leadership CRISPR-based At our against these full our the Intellia, immense clinical applications, and by broadest, delivery pipeline driving year, vivo genome laid this we Ian, accelerating ex morning. platform deepest power thank deploying medicine. beginning the We're each building innovation. the priorities: expanding building and you, of objectives. in vivo excellent out of joining revolutionize vivo making X all in novel forward solution this the therapeutic us Thank key of to the potential with technologies including company. validation a scientific industry's We're

of of being the first Liver the We the been may provide fixed the from X shared lifelong through a EASL June. was polyneuropathy first X patients results data reduction dose, treatment XX% the present the and TTR additional arm from levels the treatment the with quarter, in delivered reduction hereditary mean maximum single plan be X.X observation interim we led detail, dose with will mean amyloidosis XX. serum with serum generally of people day of evidence consist data held the the to review by achieved and has in in patients single of These mg data with updated group, well reduction ATTR landmark treated to of a a CRISPR study effect. was demonstrated in NTLA-XXXX. period, the dose study sustained our X per which dose And rapid XX% XX. day portion per TTR International a selection the milligrams that provides dose-dependent expansion reductions the greater TTR XX% polyneuropathy. Among including and in During arm. Further, investigational Congress kg kilogram therapy polyneuropathy evaluated David to at upcoming NTLA-XXXX by tolerated a

and HAE also this ATTR cardiomyopathy in In pipeline amyloidosis, as our updated second vivo arm our considerably not later we've the interim extend the in in our data development platform on we expanded display ex our our this business only multiple March, and pipeline. a data hope vivo our nature year. to advanced later from initiated first for forward sharing settings, potential ex our patient In NTLA-XXXX collaborations platform to of the look in clinical AML. the core in addition, Altogether, power gene modular reinforce vivo the bolster editing. share clinical our the full our for of as NTLA-XXXX study to for initial first confidence we but of our is and the focus. both year. that These reach data of for Switching dosed the from we of belief treatment the strategic beyond in vivo vivo in technology Notably, NTLA-XXXX treatment program,

to decades of pleased to access. we Board invaluable will systems strategy brings navigating were in and commercial our of to Finally, successfully Her Directors. improve this of She earlier care history medicines experience be innovative welcome Muna patient global Banji Intellia. X to week, health over market

that her addition, we Board skills forward have are to our relevant that essential diverse an members and In that it's appointment important areas experiences and step is most as believe the backgrounds in and introduction, our With hand plans. the Chief I'll our strategic data detail the over Medical will that across progress in David? call pipeline. who Lebwohl, detailed David greater Officer, to NTLA-XXXX company's review represent

and a and review of with I'll welcome, our everyone. XXXX data recent John, Thanks, update. begin

amyloidosis. trial Medicine XXXX There best-in-class CRISPR at was yielded Key reductions. We XXXX, landmark I to highly arm. the data updated our higher insights ongoing the England ongoing treatment investigational fundamental showed I that answer levels. we're New the in from data X tolerated with which all well of the across interim update the of treated our as patients XXXX the dose of relationship, our in for shared The cohorts Last interim part doses polyneuropathy Journal data, intended completed Phase potential escalation are X option June, have we for we deeper include developing the results dose serum people the in to from a XX onetime In candidate to from gene. precisely ability Phase begun February, all genomic ATTR living vivo dose a encouraged by our deliver and included response was which tissue edit TTR demonstrating generally target published questions the and medicine.

reductions in maximal were with with by in XX. early day months all XX of achieved dose data, that a XXXX rapidly XX% by Treatment occurred milligram of previously amyloidosis. reductions XX. dose Based maintained provides there single finding from reductions it of mean that our serum protein strong with forms is And a reduction published finally, between outcomes mean to these ATTR degree maximum the and through other these reductions TTR and reduction has durable. preclinical been and across kilogram correlation to XX% on X a levels. is per Importantly, consistent the period day This modeling are validation led a and both X observation ranging demonstrated following clinical

With of the per milligrams is of fixed reduction expected of even XX in course which to to Intellia II have Phase Upon reverse disease the completing kilogram. arm, this polyneuropathy study, perhaps to deliver TTR the far, levels persistent now I deep thus is dose a has XXXX dose we and Part halt evaluating escalation seen of the the X portion the to and milligram a potential exposure of similar

EASL to place in as well the X share that polyneuropathy supporting we from the dose XX data of study, portion the PK is at in our selection dose the cardiomyopathy XX. to to separate present the June we escalation to Liver In plan the International Congress, have per happy at dose kilogram. as taking dose escalation milligram and which data longer-term continue cohorts cohort. patient We arm are single first arm follow-up dosed of dose expansion We recently the patients fixed X.X

results dose Following escalation portion, from the move stage. we then to expansion plan dose the to

development have we for arm earlier, of observed, this to future the second the Based complete year, to the agencies, FDA. is goal will and studies arms year-end. in activity ATTR the the engagements interim of towards As John data study additional clinical and safety we including and noted half expect U.S. regulatory advance on from enrollment our include This to forms both share by amyloidosis. of ongoing both with in we cardiomyopathy data expect

therapy multiple XXXX, angioedema HAE. painful treatment our and Turning of the now with People for recurrent, tissues. to unpredictable types investigational across swelling HAE experience or hereditary of

approved patients to permanently liver we're applying remain to modular for system end, To kallikrein LNP to are in delivery therapies plasma and there that prophylactic our XXXX activity. burden and the significant. While gene of reduce treatment HAE, the knockout KLKBX protein acute the

and primate, has ability Intellia in prekallikrein As has activity XX% relevant a potential nonhuman HAE provide our point address a in To in through with period. reduction of observation humans, of reference, a currently been continuous patients. to of XX% dose, both reduction clinically significant demonstrated associated a greater kallikrein suppression in and date, of protein therapies activity activity These the for XXXX HAE burden durable which X-year treatment than after achieve to attacks. available remains a pre-kallikrein results, with reduction associated achieved the if single highlight

We dose the from fixed interim level the the trial anticipate during to the completed I/II of milligrams escalation continue second XXXX. at first Phase a in milligrams. XX our to We've XX portion initial have study year. at half dosing progress for second evaluating and of this cohort, advanced presenting data XXXX dose We the dose of

activity preliminary and results the concept for and proof expected demonstrate characterize XXXX to of these of potentially program. safety With emerging profile this

vivo ex Moving pipeline. our on to

system cell for product produce that Our treatment of the autoimmune ex cancer vivo immune epitomize approach the diseases. to is natural robust and patient's designed homogenous

of our program, our Phase more AML received in designation intracellular for of first regardless is March, TCR-based the For drug XXXX, FDA Wilms we targeting first patients overexpressed treatment orphan Tumor the X the dosed antigen, I/IIa study than also from of deploying and subtype. XX% a which we approach In in AML. with mutation the are patient the

to patients ongoing the CSO, I'll year, on R&D enroll now to of an updates expect to on our will progress platform we and continue our study, hand We the efforts. Laura, update later over provide and provide the who in this trial.

We're I'll deficiency with vivo start advancing in pipeline. David. antitrypsin or X alpha-X AATD. candidates of wholly for Thanks, development now treatment owned the our

least updates platform for and application This disease year. expect new disease. equivalent to vivo includes nominate candidates NTLA-XXXX for lyme IND-enabling and the an now tailored Stay for development file activities the a year. at AATD, insertion IND the For provides to or the NTLA-XXXX, of modular end for the progressing expect to optionality X us relevant NTLA-XXXX, candidate candidates in patient We're disease local more we for both candidate our gene liver tuned the before additional particular for our as treatment next phenotype.

that cells data readily solution created is model. and deployable T our TCR-T our and Moving data our engineering allogeneic Genome lead highlighted and for hematologic to we allogeneic cancers. internally NTLA-XXXX, incorporates presented [indiscernible] allogeneic of platform. expressing from candidate rechallenge T-cell CAR-T ex-vivo Precision and our this is year, CDXX NTLA-XXXX. persistence using complete announced first viability, cell immune a These the and evading It beginning potency Engineering treatment proprietary NTLA-XXXX CAR-T with Symposium's showed designed we At for the developed CDXX tumor preclinical protection nomination Conference, activities lymphoma which of regression the that now IND-enabling pipeline. Earlier therapy. high for candidate We're tumor in cell Kista

is X With strategy partner to the and completed and our gain of our the we've strength complementary maximize capabilities possess therapies. others rights This already breadth product collaborations. value platform, future to with who innovative CRISPR-based platform of our strategic year, to

The CDXX CAR-T candidate for focused allo an is first which Kyverna, diseases. or on select with cell advancing immune X

NK focused is X business cell gained which additional we for up across Therapeutics, to on from developing XX rights O&A commercial with therapies therapeutic the months, edited past for transactions total, candidates. CRISPR our options cancer. now have one for economic second In The

our CRISPR/CasX toolbox, In addition, we have writing our editing that to existing to DNA base are as technologies capabilities. leading such complementary added new and

additional pursue therapeutic capabilities most the each to appropriate and allow will to tool us continue We best for employ that application.

call growing support Waltham, of CFO, overview to facility therapies. agreement an production Intellia's to build our into we GMP commercial now will significant over lease capacity financial preclinical our hand investigational manufacturing a pipeline, entered support This a quarter provide Finally, Massachusetts. Glenn, in provide facility results. have our with I will the of who through new manufacturing to first to us

our our Laura, Thank in to on in Intellia we've our months, good morning, the over strategy manner. strong and to you, support maintain everyone. continues And expand to delivered past position pipeline a a particular, plans. capital-efficient financial few

of company's million by offset by $XX.X from approximately marketable program in ATM securities plans. net driven $XX.X to from equivalents in of million. of decrease million proceeds employee-based Rewrite for part million $XXX proceeds billion XX, and cash raised March to the cash of as stock Therapeutics the $XX XXXX, Decrease and million and acquisition cash, was XXXX, in as used were The compared Our XX, approximately fund $X.X December operations was $X.X

by collaboration quarter of XXXX our The million $XX.X $X.X was revenue with $X.X during quarter by million first the first driven increased compared Our during to million the mainly AvenCell. joint XXXX. venture to increase of

the upfront by R&D Rewrite, to includes which related and payment $XX.X increase Our related acquisition expansion development our of increased million $XX $XXX.X organization. million to was of of earn-out continued first million XXXX. programs of potential payment. to $XX the during a first remaining advancement our expenses driven the $XX.X $XX.X stock-based to by lead quarter was million driven and during The XXXX, the $XX.X a This compared million by quarter expense of the million of million

compared to first XXXX, to XXXX. increase the This employee-related million during $X.X compensation Our was first mainly of of of $XX.X quarter expenses, stock-based million million. million G&A $X.X increased quarter related the to including $XX.X the during expenses by

balance fund for months. that, Finally, we next our remarks. I to operating With closing beyond over expect our call cash to back John the turn plans the XX will

XXXX you, progress strategic priorities. already against Glenn. Thank making We're significant our

robust pipeline, including the in and programs owned now partnered programs we're advancing clinic. wholly [indiscernible] with First, the

With in Next, financial development any position accelerate our about key to therapeutic happy platform remain we licensing of in outside we're to a of us realize programs areas pipeline for answer areas questions Further, to our importantly, our in strategically enables be platform. investment that we'd we're vision the expanding our new continued with strength And focus. technologies that, Intellia. innovation.

[Operator Instructions].

The from Swapnil Sandler. comes Piper first of question Malekar

Great.

is especially follow-up. per related X to fixed mg then a in exposed with safety? concerns first regimen, there I any kg the to So patients might who than dosing are have get And lighter X dose, more

your safety? about how you and we fixed dosing David, want think to views do give on the

the at Fixed that dosing Yes. X. all as had on we Part looking data going to was were based we forward

point, we saw in from months. in February to a And So that were X recall what was with in deep durable it part patients. average X follow-up you reductions, XX% X, and variable at reported XX reduction that

our was EASL. weight have it patients will We the more showing patients. this exposure you presentations details PK is of And also not from that And the that showed upcoming the affected be then work. what of we significantly at the by in of

your much -- the same patients and So what size patients how related that that the though, really and is your is are our the weight We is where drug, exposure think what of depending matter is on essentially drug. that out. of fat is or that's small target fact to coming not, this means, liver the larger that and no that's experiencing similar, the -- exposure

to deep will move forward found to this what I of then tested able course, be So we to further type we X, good that reductions, the going will in expect be want we and part and studies. of confirm what from forward, Part safety the we same is see

follow-up any do for on transform Got little upsized premature and trial thoughts a have bit implications its IMS' but for future it. And extended Intellia you although cardio pivotal And trial? is to then trial? duration a discuss, the cardiomyopathy to strategy X

trials. help BridgeBio us we trials have certainly, moves to come X did trial, inform We some going from looking a Alnylam trials to from is they're little trial our about as of learn any a do, of things their are we're will they going trial. look they're but forward the at the to the know and and move bit will robust really not forward. the it. as we late they Yes. from announcement important based from is for some to data it's really What What's on ongoing That the said saying more it

The next question comes Jefferies. from Maurice Raycroft with

XX can to one this to half higher on proof-of-concept this like going that's point needed? you second I'm do Or ask you than fixed? mg data was at dose for that on And preliminary could decided HAE. I you if not wondering know of look year? what elaborate have

as in about the you there's releases there. year for data But probably of what and a store Maurice, maybe a David, bit goes you have about trial? progress of the dosing lot little questions in are talk thinking the that more do can We how on.

Yes.

we've HAE, lot is approach. a think So times, using for I this modular said of our

is what's from and we learn XXXX. here could important So in we what XXXX it to did bring

dose. of XXXX per that, we the started product basically One equivalent was the start lessons the to those doses? higher And early at the used milligram important XX a what's is which trial. kilogram X.X in the milligrams, with safety of at dose at We that did is

We the XX you similar level, the said, will to be be which in XXXX as that dose dose the highest we was trial. dose, would data milligrams, higher at bringing treated forth next the

this do seeing actually and terms we pre-kallikrein see in we second we've the we expect in And with the that from looked biomarkers in seen what what in that, and of be levels decrease a a report at associated we particularly proof decrease trial. XXXX. this be likely very to previous in on and substantial. So the the of rate, is are know in safe to very based could of year And other is half in concept, expect attack both as activity being compounds, what to

think lost Maurice. just may there. we I audio have I David's up can finish

we in to we'll that and position principles making we've terms position applied judgments the in talk and to think be where those sufficient this of effect the we point make ties in that about sure, that share if same about can't share guarantee view, consistent. it a be we're the point we'll to observations to I in past those the rates a And because on clinical a significant, the characteristics attack time of at For the down of position patients. having a can and from apply biomarker. that in we'll interpretable And

we're -- position try to share certainly a as well. that that, if will in we'll We to share

maybe Got really it. helpful. That's follow-up. a quick And

study into about types HAE can Or... If that enrolling baseline rates of the as you attack you're the point? this talk as patients at far

want course think rates disease there's requiring several the not everybody of mean had have attack I are have obviously I a to and attack in. threshold the level. the determinant. within have really attack a -- they high we a a the that we're all rate not with primary expected diagnosed instances Well, But is should There's period, get X-month these be to time over that rates of attacks observation period. to it's

And patients so the a then that's time why baseline you need thereafter. have sufficient to a observe to and

The Dae of comes next Gon Ha question from Stifel.

I'll and X on question. I can, more X-part question a it's add XXXX if

So I first hearing think if mg, this not is XX time the we're actually XX and about mistaken. I'm the

per look a So final that first was data correspond there cohorts? scaling? least comment looks And able cohort part when got are or cohort, you presented the fixed cohort about in end what would this year, is, follow-up. dose since completed? and what the to And be think NHP at of like we I've you end AI mg NFX each XX X dosing, these level was in the your secondly, And just to to we when at on XX what allometric at first last determines will Quad that

to highly doses we're the XX heavily the preclinical program. from to that question. three-part fixed And is the drawing that how that and is dosing and what TTR. just using spoke derived the related referred at of respect David dosing form highly, XX results a from looking in TTR that relates With all to to, we So

purposes -- I there's done additional an it looking with more to the from NFX if is you the reached. do how large the than if when animals, a were the of sort patients respect if X, cohort. drives final cap by to extrapolate activity and cohorts a but some And the a an to it approximately more are guide, number because cetera. of to toxicity that the of animals question, The as the of how similar would TTR consideration that's got to if you than complications take expansion a final divide within rule I humans. try want starts you et determine thumb, So of dose Dae? program, this, dose-limiting But you to it's get complicated discussion, would patients to into of That with we've With rules to simple are, second X that repeat patients. your number for

think I it. of all that's actually

the or characteristically I that correct when you just XXXX on the can does XXXX? either going liver I selection XXXX XXXX, follow-up when in lung, that tier And is is curious to from the vivo the up after going next? to about in the XXXX before guess, I the lung might guess, be different LNPs, So just the and I the be -- we question, it presumably which assume guess XXXX LNPs think remarks, another go on year-end the prepared to in is ones alluded used and 'XX. candidate imply program and progress XXXX into

the of and program, XXXX an we're the the of remember things that it's is remember XXXX, whether one that AAV XXXX that all an XXXX, doing as Well, is work component. liver, NP hybrid-based the which or targets to

modular or that lympho show the the so beginning, elements, last with and approach starts which in with this same the of XX RNA. consists of which the to of mRNA nucleotides all the are goes guide exception highlighted RNA from the we've the back of guide the same cargo All essentially the

the transgene way. very inserted. respect there a all is that these the XXXX, just to it I bringing AAV in with to delivering equation we're very, extensive So way think and into be With LNP, similarity, across of as programs, would about a

to of the each source really lung and And alpha-X disease. aspects target and gene progression both the of antitrypsin protein targets of the or a the of that's independent that and the XXXX defective while forestall we're about XXXX XXXX is XXXX thinking itself they're wild-type deficiency, way of production distinction. other. XXXX eliminates protein they So

them differently, that's the sake, would So think be to warranted. in but at we single a we patient them merge we position that within for a if end treat simplicity's

Salveen The Instructions]. [Operator next Sachs. question with Richter Goldman comes from

as if program paradigm current fitting HAE see just do see you the you these patients? optimal here well, profile, into for the on do given an where the Just it treatment options

David, a audio do But We David's minute treatment David, fits for lost back. this you're you there. -- want do think I the -- you where HAE think into of patients? to treatment

for Sorry my disturbance morning. this technical

this So in is to see would prophylaxis. to What attacks and be that we course, those in you even been treatment, and levels. XX% expect reduction get higher what's than of reductions would to getting would a range a compounds greater better you seen with the XX% have perhaps other as XX%

is inconvenience, So prophylaxis Where patients. we injection have, pills, right we the prevent discomfort, by in, injections patients an of taking injection. for attacks either the want the in would this that of better onetime work the pills. people by now, sits think, lifetime what would potentially cetera, getting a or are treatment avoid The because that but general et to than the many of

being occur preferred really with any the that patients. treatment onetime that would of think by reduction, that also prophylaxis, -- we So issues become a could and getting treatment levels both for this patients recovery prophylaxis at avoids excellent any continuous issues, the for it's

& Next Company. with question Cohen comes Thome Joseph from

patients be you those long want update, follow you functional EASL symptom at in provide the to update some a we terms this how Just polynopathy position see out do to for? data in when of this be would time? Or to able maybe will

data David, why going are see clinical we polyneuropathy arm? to some

Yes.

So later measures at in arm, treatment. polyneuropathy the come points those in

long time it it not to get take So yet does for a EASL. and available

what's reductions know results reduction. type and mentioned, seeing, as of achieved do is results, to XX% that other we agents, with potentially expected better patients. better This with is than the with for also what and However, we're been achieve clinical

you look types clinical you have, the patients available of from lower the their better the silencers, at if look outcome. amyloidosis, protein that at data If other

studies -- the will do so other this with we happening depend on data that's to of we type show, clinical the won't what but to predict effect. of results So be have

Securities. Joon Lee next The comes question Truist from with

the on [indiscernible] on Joon. for is Congrats progress. This

the in related two, So seventeen. has XX% basically after reduction prekallikrein reduction and to -- question [indiscernible] our HAE. five, month a [indiscernible] question is XX% first attack done one, rate

this be So reaching goal what is in how you the levels question surpassing treatment? at least for your them? are And would or these confident

data. we'll including of modality far, a accumulated the certainly the think more our ultimately payers virtually about I'll various so far, patients, that achieved perhaps been be but extracting first surpass we're from way that. mean those Thanks data and pretty confident Maybe elements the some we its I that for in and TTR HAE data including are somewhat is treatment recent that and we've there's disease to itself. address. numbers position described, meet want address are we is treatment to for doctors the what's on Obviously, think going -- based and any The thus in preclinical that representative entirely the just question. you And to

young, seeing to said very we're here. think right be think backdown the there's [indiscernible] earlier, I attack on clinical accumulate we we're But ongoing in is track to These takes patients view, are disease data in couple if from So I ongoing additional otherwise trials, X it get what they're including effects. adolescents. these those troublesome the that the if patients. you and point And sometimes pretty the oftentimes, of Number go treatment people elements the devil, as a in rates And and interested as treatment activity Obviously, ask we the doctors, needs data of also [indiscernible], an all point accumulates, of from to that that of a one normal is we'll confirmed ask other view. share elements study. you of it.

the #X a major cost lifelong itself. that medicine costs potentially as over in that's advance an million which access of element States lifetime attacks effective of one over onset, think certainly therapies. their once tell there's patients. the these $X issue, you the these year, us. have treatment for to for for the number it's burden treatment of you a within just sort But when what And they're of be patients patients, look believe is extraordinary diagnosed. the And so of patients. United And somewhat the we particularly control, will are and of of those Many done these and a which the well, is another alone age patients And the most doctors certainly the if a when

an system. these a And on from economic of improve of that patients there's we to opportunity so believe cost also point health and the care the view, massive to

the for that we attractive recommend very to as editing will considered other is all drug -- very, And I very available. intervention we physician. received. But Salveen payers, doctors And paradigm, the be I well patients gene this treatment these I first family asked the I doctors, think I going a as that all think be wouldn't things it attractive cetera. there elements members, are think going offering in when et to I the about and expect scheme of understand that is accumulated. certainly, question a the will this, this So of think about be patients, mean, don't treatment it's think the will as caregivers, that information do. for be performs, of how you elements

That's very helpful.

with Chattopadhyay next Debjit Guggenheim. comes from The question

This is Ryan for Debjit. on

question the the of hypothesis In curious as preclinical KOL may any has feedback through negative for offered our some see for outcome Intellia you in do precedent AAT studies? there for Is Just the And/or discussions, insertion loop. XXXX, interim data suppression or was expression second XXXX. this? phenomenon a in great of good readout? observed this PiZ for that wild-type what of And a result

with a XXXX. But readout. Laura is Well, address what to first, to let XXXX to and do good going think we data turn respect me I'm

some XXXX the patient. perform, that's mean XXXX -- how think But to the indicator most do the I its and is in guide cetera. been rates. have And to setting to range attack terms program. final they matters to see in certainly to is I'm relating levels of readout gets our approximate is going et the the different sorry, whatever differences, we've what of own these going the the data expect itself idiosyncrasies. expectations I where be one TTR And programs the we have editing knockdown of some of important patients knockdowns. But all of would

we And knockdown a on so are that be lags that's a story. story going to where

to advance patients transgene say, Laura, would you to as the said, speak I about expect want the to how think later to with we the underlying share would want the see to you accumulates. XXXX introduction data interesting an and and it that in as this efficiently let's we'll develop I story year So how I do of would as mutation? see possible.

restore yes, the Yes. you to that's heterozygous And you're so do able share there So good of ready one the if phenotype with we're we is the themes right, of type be pursuing may expression the the we'll of [indiscernible] to those basically, possibility XXXX. data right? share that you have when levers, are in it. And

from next with Gena question The Wang comes Barclays.

program. HAE XXXX the regarding one Just

jump in to do level knocking like you you to higher I given John, the would previously wanted look do that And achieve would remember, you level of ATTR benefit. reduction. maximum down? sufficient at even XX% lockdown X.X reduction beyond clinical X.X be that Or you from because you achieve? to kg, per your wanted Was that mentioned program XX% the dose, milligram wanted X.X per translate we milligram kg to is when to of So to

where et the of alpha Gena. the systems potency. while elements own Well. thanks question, its same, for to guide with respect mean, characteristics the are modular of it's these HAE will individual from things. I cetera. have first Remember, essentially TTR Each to X, all, to couple a going are

comes from we're need response kallikrein, biomarker establish, we're do the that numbers, exactly And and can that's just establish those believe a curve. so HAE from of asked meaningful work relationships going drive of of these We of numbers those profile really others how patients that to relate the We But for a those drug this we down to we're which is the that would to the clinical we stock that need that's outcomes. a believe those certainly we do advances striving for be to were ultimately using. expected questions illness and be dose And knockdowns establishing what sorts that we the the assume. to can't attack drive And expectation for. may curable them. what readout to be what to been work. in the extrapolate the we rate, here, advance of have what's who doing are before, ball doses So individual that will deeper it see knockdown and likely relates our what's that

be really dosing Phase would fundamentals for and and best that make what drug play particular having I for by we that a study forward what's our in we'll make from readout will a think perspective the carry we judgment So start as judgment of that to It's information we the I a into wouldn't out the registrational are go, then doses the mind. study. I so But the can which going development. good be look number

John, that like you'll looking the in level? for like you knockdown for would past? that looking be like Will the XX% knockdown mentioned also be targeting the you number specific be

clearly go good zero that and we said to beyond that beginning, pretty with levels that have relates the And we've and see from We what the they've tech XX%. that had. outcomes much to want

we well going clinical where readout. good get go reduction be believe you're the be those of to data, threshold relationship about will The Tina testing levels think clinical for data. So XX% XX% because of we the we going in the a beyond really, would is And terms biomarker us and drug that to that's that absolutely the outcomes. to though, Gena ultimate really clinical be how with

from Luca Next with question Issi RBC. comes

the editing. one. on on guidance issued a recently gene FDA Congrats progress. Maybe the quick The obviously

comment how was So you're a that on you and have wondering document, if maybe first take picture, I your can follow-up. bigger implications your on And IND. filing for what about thinking

its we programs. benefit characterization preclinical of say, elements there's It's the in guidance we really we read And how it some, there's various the It's that effects very work. about with the target the the how run -- We off there. think of drug. conforms limited initial own I'd guidance, As the and the own point is its risk, that think exactly FDA tend programs. I with considerations thing to to programs. guess all where was these the particular program with I we speaks with each which clinical start fundamental respect be they to just about the think is clinical on

surprise was real us. to So it no

that saw much guidance. most Our view addressed of is considerations that in the the we've pretty we

it. laid well the much wasn't think think requirements the we're the different surpass of discussions So regulatory appropriate. that or that I By those added in to certainly what's into guidance guidance work out And the of changed how with doing with the documents. to there respect we're specificity including we that about and really FDA that agencies, address the way, is

I off-target the think any in characterization, think active seen the we for have welcome the least people is point publication that additional company to from adequacy about Journal, been addressed as FDA out. interest a the coming we back our high have which we've one in things good as think guidance New had it's we a the the and of you'll And into at we standards laid strongly standards starting there. have in England the But very that space. of it's feel is space

helpful. be appealing, on sublicensing maybe I IP? Broad know how it. ultimately Got is agreement but then obviously should from the CVC the the thinking Got Super thinking And you're latest decision it. what's potential upheld? quickly, about

And findings bearing play no Sure. decide is progress all to our the funding the said patent progress very outside what of interest, their how of own or far with work do. incomplete. to out. process we respect thus everybody's as this well. these a The ahead process speed do. if in on findings think, choose do far, very, that none XXXX, refers have now to The or including we with progress do area to, since what that want the it's we we I full Broads thus they that affect how limited particular It's programs. work to We've will we The

I'm at I it will some get the to legal ways process other -- doesn't there's point, be So agreement think sure there out, an play here. to

James. Seedhouse The Raymond of next Steve question from comes

Steve. for on This is [indiscernible]

us So in just question the a for EASL presentation. of quick terms

didn't So you've of mentioned and of itself -- see time? efficiency you edit percent presenting to to biopsy. Will liver any over data maybe measure mention see present exposure biopsy we editing a details

to all kind might get. and biopsies than read risk any present. because matter, and not that We more benefit to No, informative no that that one investigators that's there's for and patients particularly subject of regulators analysis probably

to provocative subject you the England anybody was a targets. far off-target about primary far would of and in and And that. these donor Journal, agents where higher cells. healthy that, can and on do who's the basis we them hepatocytes that space looked just a biopsy manyfold now work adequate to than believes informative testing New editing an that of defines less for more of probing published aspects think off at is look think that this information any provide done are profile that's take levels of I with the which we've it's what These concentration, preclinical

from SVB question Foroohar Mani with next Securities. comes The

specific call. with some alpha-X and seeing are and that little in programs along. we're more, tagging to this atmospheric Obviously, there's from a Something you broad questions I most of a of data going little the guess, antitrypsin individual guys about

You cell platform? with have reasonable delivering we part at the sickle modularity to it on you some time was the what of seeing in partnerships us Can of illness specifically. your line about outside comment think liver? looking an the And for start diseases of as bone of human should how marrow modalities is, some data

liver? disease liver-related disease considering you consider you So think the Are lung a do Mani? do alpha-X of antitrypsin, about that that disease? you How as outside

since your editing consider construct primarily disease would I to hepatocytes. delivering related they're

Yes.

Okay.

lines, within a cell. So the some But time candidates of interest talking that we and about I clinic. work today. means future done I the of can't have that we we've as for for more development et the of company other to to here, marrow disease talked related on these those start we have going give liver. beyond share the moving diseases, what lot the present programs. specifically about matures, programs that we've there's that And cetera. think then of preclinical in and would be the of But thinking been that. level, related guidance some And bone we're in sickle that about to immediate data ones in work we going There We've and the can terms are

from Zhu next Yanan Fargo. comes question The with Wells

for So in first, with March presentation? incremental expect durability, we additional the all EASL on the terms months of durability patients could compared X presentation, your

about just to do want a at say what expect David, to word presentation? you EASL the

Yes.

start So in the cohorts more had with follow-up. here before, mentioned a will we -- we as XX-month follow-ups. additional about fill had we And to mentioned, you

that do patients to So the very that talk that we'll able we reached get with their data additional will follow-up, itself. speak who've when will think be And valuable time. for we we markers about think important be number there, of in

we really soon. look that showing forward to So

in three it's monthly think data the progresses, to I I important that is intervals. add the think David maybe study as accumulated,

data present quarterly a in individual in time, phase, so comes And a as these observation while the early it of increments. have are we essentially of lot to for longer period followed patients points

I this. way about think And forward, going so that's the

goes XX months. XX actually, it to from And

is the expectations. a to month But so make for in XX gap very there we'll So the presentation clear point. point, time what XX that big from the

or over on is my disclosure Got it. at question week, the the just That's for weekend. very last your meeting Keystone XXXX. other helpful. this And Thanks then actually

CDX out to CDX regard with the both or X from to rejection NK NK knocking approach your address receptor of and So cells. cell host

presented host HLAX how data be at there still about that's according compared with the I knocking not complete should will this conventional for activation approach HLAX HLAX, think eliminate But and elimination CDX down you in to knocks completely any we why receptor think effective eliminate this aim does this preclinical you more of Keystone. HLAX. order is didn't to rejection, but because prevent knockout did not out HLAX, probably the approach? some How

showed not speaking, Laura, here approach that that Laura characteristics edits do comes we're contrast we the you presentation, we doing. precise on generally make. add with But disclosed taking we're what yet to hasten want that we've -- to what while I the we just at attempting the that see achieve. to others we're

is exactly attributes we describe the want what XXXX? of why and about you Laura, these just excited it So want to cells that we're in

X sorry, yet data need And are doing you drive the the we ourselves we but overcome they able rejected sold immunological activity. with antitumor problems, there not allogeneic that supporting activity on by efficient that to exactly rejection we're all time, but with have that retain for ensure not are the mutations, that we're to it, been addressed Yes. it And work right? believe not that I'm what development, NK how do by our other they now others therapies CDX do degree. on-target disease, prevent a in that clinical there's prevent technology, with cells. right? we T at we've it's in So and allogeneic all rejection some that it's prevent is cell cells. same And concern to NK host then CDX and effect, versus short very cells. So And graft doing by duration was the of The are therapies to

M&P do highlight an they to allows base have that are engineering our The other thing and with manufactured can generated not high-quality to be here high-quality sequential editing using we these cells engineering, are very us exhausted that Intellia that and process where is cells that attributable.

is brought the Kyverna our we for company. this XXXX more have work forward Laura relates example shortcomings partners about One and to product team approach standard approach and the essentially understand the moving as allo with is first the of view work But there. thing that a out done own to to that platform of her add what we've and wholly as the [indiscernible] allo where, owned the forward. it their

to to bring I what for ability about but and shelf, something we excited and differentiated this also have the beyond of approach the think our that's going people say. eliminated reduced very essentially off immediately, increasingly solves persist to completely standard is can X vastly there are poor what it which patients, or to true performance be and whole fairly we X that should weeks in tend within -- that graphs or the approaches approach I think deficiency, number where judgment, and this

will The from Oppenheimer. of Jay last come question Olson

you your on how preclinical of you're a and allocation? early-stage of have how programs pipeline clinical all overall Congrats Since those in large progress. prioritizing number you the optimizing you're your Can talk also capital about programs programs.

generate and important advances with approaches, I within differentiated known It's medical to there's you From pursuing it's of appreciate really within bring lot wanted lots that are because to that just to reaches the pipeline level be we by the it. and question, Yes. asked to our a going optionality a that expectations. if our cetera, et modalities a outset, highly and important cetera. there's learn. they mean new the et new perform I company We start that we've platform, targets we've really think

speak of forward. saw very, in that You'll to somewhat that enthusiastic that with approach the the TTR results vivo work. a broadly see program, in us very think we modular about the across that's bias vivo move The the allows something we're we and to pipeline,

that we that platform up space And to receptor ex crowded, us gets a answer understand once in outside will side, what convincing extremely then right a B-cell-driven space. we an and very, we mean, approach do the important forward. and as T-cell with narrow doing we've very is how think created, to it interested step very because programs those now, in vivo the understanding our we're out. try to I open a play we're fashion. On question, very performs CAR-T we the What is largely a stepwise isolate

platform extend the is our then the our the work appropriate technology as high work we most with working showing elements any look will, possible to any of we've And it the together, and even we're we on. level. for collaborations pipeline as we best accumulate products. to the important And of that decisions as X is we appropriate performs taking and by So that's we to reach. that what done, other us. at reach attributes prune perhaps make from in the doing, think individual it. that X forward just And see that complement way But of the allo think favorable the way aspects identify you'll that's we're and as best move

This like to the back turn Karp concludes session. conference would over Ian closing to remarks. our any for I question-and-answer

continued and in you on a support joining look Great. the us Thanks great to for Intellia forward everyone, so certainly today Have and day. and interest and much, updating progress in future. we thanks, your our

Thank The today's you conference has now attending presentation. for concluded.

may You disconnect. now